Log inSign up
user avatar
Charles Roberts
ARK Invest
@CCRobertsARK
Chief Investment Strategist, Private Equity @ARKInvest; techbio cofounder: AI/omics unicorn Freenome, Relation Tx. Disclosure: arkinv.st/terms
linktr.ee/ARKInvest
Joined June 2017
3,284
Following
59.3K
Followers
  • Pinned
    user avatar
    Charles Roberts
    ARK Invest
    @CCRobertsARK
    Apr 1, 2024
    Will X ultimately become a fused collective human consciousness? @elonmusk talked with us for nearly two hours in December last year about the paradoxes on his unique mind. Given AI advancements since, his thoughts are more poignant than ever. Read my reflections on this
    user avatar
    ARK Funds
    ARK Invest
    @ARK_Funds
    Mar 27, 2024
    A few months ago, ARK's Chief Futurist @wintonARK, Chief Investment Strategist Charlie Roberts & CEO/CIO @CathieDWood engaged in a wide-ranging X Spaces conversation with @elonmusk. @CCRobertsARK wrote a reflection on their conversation & ARK’s thesis on X.
    99K
  • user avatar
    Charles Roberts
    ARK Invest
    @CCRobertsARK
    Jun 16, 2022
    Replying to @KlendathuCap and @InvestorAmnesia
    Companies that sell red lights
  • user avatar
    Charles Roberts
    ARK Invest
    @CCRobertsARK
    May 3, 2022
    Biology isn't a software problem, it's more like reverse-engineering crashlanded alien tech!
    user avatar
    microscopic images.
    @microscopicture
    May 1, 2022
    most detailed image of a human cell to date
    Readers added context
    This is a digital representation of an animal cell, not an actual image nor does it involve a human cell. snopes.com/fact-check/ima…
  • user avatar
    Charles Roberts
    ARK Invest
    @CCRobertsARK
    Jan 22, 2021
    Replying to @ARKInvest
    👀 So excited for people to see this. It’s been a blast to work on. 🧬
  • user avatar
    Charles Roberts
    ARK Invest
    @CCRobertsARK
    Oct 22, 2021
    We hope you'll enjoy our newest work-in-progress (WIP) piece on Ginkgo Bioworks, which couldn't have been written without ARK's newest #genomics analyst, @PierceARK. Give him a follow!
    On Ginkgo Bioworks
    From medium.com
  • user avatar
    Charles Roberts
    ARK Invest
    @CCRobertsARK
    Jan 5, 2021
    A Thread (🧵) Let's discuss long-read #sequencing, optical mapping, and the implications of a recent study (linked below). Please view my disclosures at the end. I've intentionally made this thread more technical as I think it's necessary. biorxiv.org/content/10.110…
  • user avatar
    Charles Roberts
    ARK Invest
    @CCRobertsARK
    Apr 19, 2021
    I'm stoked to announce that ARK is hiring a Genomics Associate to work alongside @aurmanARK and me. You don't need a PhD, just a voracious appetite for new information, comfort with unclearly-defined problems, and a passion for the life sciences.
    Job Opportunities | ARK Invest
    From ark-invest.com
  • user avatar
    Charles Roberts
    ARK Invest
    @CCRobertsARK
    Jun 4, 2021
    I constantly go back and forth between being elated about advances in ‘omics technology and bummed about healthcare incentive structures that keep the tech from being widely adopted. Rinse and repeat.
  • user avatar
    Charles Roberts
    ARK Invest
    @CCRobertsARK
    May 25, 2021
    Molecular diagnostics pitches nowadays ...
  • user avatar
    Charles Roberts
    ARK Invest
    @CCRobertsARK
    Jan 13, 2021
    I've gotten a few questions about how the FDA regulates medical devices, chemical reagents, and diagnostic equipment. Quick Thread 👇
  • user avatar
    Charles Roberts
    ARK Invest
    @CCRobertsARK
    Mar 18, 2021
    I've taken a stab at a #proteomics series on Medium, this time with a focus on Seer (SEER). Take a read: medium.com/@sbarnettARK/p… Broadly, I'm experimented with Medium as a replacement to writing overly-cumbersome Tweet storms. Like it? Don't like it? Let me know.
    Proteomics Primer #1 (SEER)
    From medium.com
  • user avatar
    Charles Roberts
    ARK Invest
    @CCRobertsARK
    Feb 11, 2021
    Gene editing companies use DNA #sequencing to verify their edits and scan for off-target effects in the genome. Now that protein degradation therapies and proteomics tools are gaining traction, will protein sequencers fill a similar 'proofreading' role? nature.com/articles/d4158…
  • user avatar
    Charles Roberts
    ARK Invest
    @CCRobertsARK
    May 31, 2022
    Check out my newest research on single-cancer screening and precision #oncology. Here's a summary thread: 🧵...
    Single-Cancer Screening Could Transform Cancer Care Diagnostics
    From ark-invest.com
  • user avatar
    Charles Roberts
    ARK Invest
    @CCRobertsARK
    May 11, 2022
    Some comments worth repeating -- DNA Sequencing, Molecular Diagnostics, and Life Science Tools aren't 'future tech'. They're here. Right now. Generating $100's of millions in annual revenue. You also don't need FDA Approval to launch products in healthcare.